Integra Lifesciences to Present Innovative Gene-Writing Technology at ASGCT 2025 Conference
- Integra Therapeutics will present innovative gene-writing technology at the ASGCT 2025, enhancing cell therapies for oncological diseases.
- The company’s CAR-T cells demonstrate improved efficacy against B-ALL and autoimmune conditions, revolutionizing treatment possibilities.
- Integra’s novel CRISPR-Cas12l nucleases and viral-free FiCAT platform aim to advance safe and efficient gene editing technologies.
Integra Therapeutics to Showcase Breakthrough Gene-Writing Technology at ASGCT 2025
Integra Therapeutics, a frontrunner in gene-writing technology, is set to present significant pre-clinical data at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), scheduled for May 13 to 17, 2025, in New Orleans. Dr. Avencia Sánchez-Mejías, CEO and Co-Founder of Integra, underscores the importance of this presentation, which focuses on the company’s innovative gene-writing platform that achieves double-digit editing efficiencies and facilitates multi-gene integration. This advancement aims to enhance cell therapies specifically targeting oncological and autoimmune diseases, marking a pivotal moment in the field of gene therapy.
A key highlight of Integra’s research is the development of CAR-T cells that utilize complex chimeric antigen receptors (CARs), including bispecific variants equipped with a kill switch. This technology not only simplifies the production process of these therapeutic cells but also significantly boosts their efficacy. Preliminary results indicate that these CAR-T cells outperform existing methodologies, exhibiting a greater capacity to eliminate B-acute lymphoblastic leukemia (B-ALL) tumor cells, while also showing promise in treating autoimmune conditions such as lupus and rheumatoid arthritis. This innovative approach positions Integra at the forefront of advancing CAR-T cell therapies, potentially revolutionizing treatment options for patients with challenging conditions.
Moreover, Integra plans to unveil results from CAR-T cells generated using novel CRISPR-Cas12l nucleases in combination with their FiCAT platform, developed through a strategic partnership with Caszyme. The data suggests that this new methodology offers enhanced efficiency compared to traditional CRISPR-Cas9 techniques. Among the critical topics set for discussion is the "Precise Gene Writing System for CAR-T cell therapy generation," which aims to address existing challenges in gene-editing technologies for ex vivo therapies. The FiCAT platform stands out as a groundbreaking solution, providing a flexible and safe means of editing both small and large genes in primary cells, thereby pushing the boundaries of gene therapy applications.
In addition to these advancements, Integra’s presentations will highlight the development of a "viral-free FiCAT gene writing platform for liver-directed in vivo applications," scheduled for May 14, 2025. This focus on creating safer and more effective gene editing technologies reflects Integra’s commitment to driving innovation in the field, ultimately enhancing patient outcomes and expanding the therapeutic potential of gene and cell therapies. As the ASGCT meeting approaches, the biotechnology community eagerly anticipates Integra's contributions, which could reshape the landscape of cancer and autoimmune disease treatments.